Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Remote live-cell imaging system

October 2020—CytoSmart Technologies launched an automated live-cell imaging system designed for long-term experiments, comparison studies, and large laboratory teams. The CytoSmart Multi Lux consists of four mini digital microscopes supported by automated image analysis software. Multi Lux technology enables users to run up to four experiments simultaneously from inside the incubator. Automated image analysis and immediate visualization of the results are accessible remotely via the CytoSmart cloud.

Verichem standards kits

October 2020—A ready-to-use microprotein standard kit is available from Verichem Laboratories. The kit is intended for the calibration verification of total protein and albumin concentrations in urine and cerebral spinal fluid. The five-level set provides 10 certified concentrations in an azide-free liquid format. The kit is suitable for use with turbidimetric and colorimetric testing methods and incorporates human protein components. Shelf life is 24 months from the manufacturing date when stored at 2° to 8°C.

FDA issues EUA for Yale’s SalivaDirect

October 2020—The FDA issued an emergency use authorization to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection, the agency says.

IVD immunohistochemistry assays

October 2020—Novodiax released two rapid ihcDirect reagent test kits for in vitro diagnostic use, ihcDirect CK19 and ihcDirect CK20.

Clinical pathology selected abstracts

October 2020—Early in the COVID-19 pandemic, some reports linked ABO blood type to severity of the disease and test positivity. Among these were reports that blood type A was associated with a higher risk for SARS-CoV-2 infection and blood group O with a lower risk of infection and mortality. However, there is a paucity of data regarding the relationship between ABO blood type and severity of COVID-19. Therefore, the authors conducted a large multi-institutional observational study to determine if there is an association between ABO blood type and severity of COVID-19 and if those with specific blood types are more likely to test positive for the disease. For the study, they used a large multi-institutional database of adult patients who tested positive for SARS-CoV-2 at five major hospitals in Massachusetts from March 6 to April 16. The authors evaluated hospitalization, intubation, and death for an association with blood type.

Anatomic pathology selected abstracts

October 2020—Immune checkpoint inhibitors are frequently used to treat a variety of solid tumors. These drugs involve upregulation of cytotoxic T cells, which can lead to immune-related adverse events, including those involving the gastrointestinal tract. The authors conducted a study to characterize the histological features of immune checkpoint inhibitor therapy-associated gastritis. Gastric biopsies from patients on immune checkpoint inhibitor therapy who had clinical suspicion of drug-associated gastrointestinal injury were identified. The predominant histological pattern of injury, distribution of injury, degree of tissue eosinophilia, and prominence of apoptosis were recorded.

Molecular pathology selected abstracts

October 2020—An increase in the number of copies of a gene, or amplification, is regarded as the most common gain-of-function alteration across various cancer types. The authors developed a bioinformatics tool (Amplicon Architect) to identify extrachromosomal oncogene (ecDNA) amplification from whole genome sequencing (WGS) data based on three characteristic features: circularity of ecDNA, absence of a centromere, and high levels of amplification. The tool was validated in 44 cancer-derived cell lines known to have ecDNA. A combination of centromeric and noncentromeric FISH probes was used to identify extrachromosomal DNA, and the tool was able to classify 83 percent of these signals as representing circular ecDNA amplicons. Interestingly, some of these cases revealed the presence of concurrent extrachromosomal and intrachromosomal signals, suggesting that some ecDNA had reintegrated into the genome.

Newsbytes

October 2020—Many prolific Twitter users describe the social media site as a time sink, but Andrew Schaumberg, PhD, begs to differ. After observing pathologists turn to Twitter to seek advice about difficult patient cases, he developed Pathobot, a free, artificial intelligence-driven search tool on Twitter that is designed to help pathologists connect with colleagues faster.

Put It on the Board

October 2020—Siemens Healthineers will collaborate with the Centers for Disease Control and Prevention and the Joint Research Centre of the European Commission on a research project to develop a novel process for standardizing SARS-CoV-2 assays.

Bruker introduces MALDI-2 source on TimsTOF Flex

September 2020—Bruker announced an advance in matrix-assisted laser desorption ionization with the launch of its MALDI-2 post-ionization (PI) source, now available as an option on the TimsTOF Flex ESI/MALDI mass spectrometer. The MALDI-2 technology can offer one or two orders of magnitude higher sensitivity for many small molecules and lipids, Bruker said. MALDI-2 increases the applications range of MALDI mass spectrometry and imaging even further. Bruker launched additional TIMS/PASEF-enabled 4D proteomics methods that leverage the large-scale, real-time availability of accurate collision cross sections (CCS) for thousands of measured peptides per 4D nanoLC-CCS-MS/MS run.

MARKETPLACE

TRENDING